Wholly Owned Pipeline

PureTech's Wholly Owned Pipeline is focused on the lymphatic system and related immunology mechanisms for the treatment of cancer and immunological, lymphatic and CNS-related disorders. 

Wholly Owned Pipeline

Our programs
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
Lymphatic flow disorders, incl. lymphedema
Readout from Phase 1b MAD study & initiation of POC study in 2020

1

Lymphatic flow disorders, incl. lymphedema

~1M

Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).

LYT-100
Deupirfenidone
Serious respiratory complications after COVID-19
Initiation of Phase 2 study in Q3 2020

1

Serious respiratory complications that persist following COVID-19 infection

Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
LYT-100
Deupirfenidone
Other fibrotic & inflammatory disorders, such as IPF

1

Other fibrotic & inflammatory disorders, such as IPF

~130K (IPF or uILD)


Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).

LYT-200
Anti-Galectin-9 MAb
Solid tumors
IND and initiation of Phase 1 study in 2020

Preclinical

Solid tumors

>50K/year U.S. (Metastatic CRC)
>28K/year U.S. (Metastatic pancreatic cancer)
>4K/year U.S. (Metastatic cholangiocarcinoma)


LYT-200 is an investigational, fully human, IgG4 monoclonal antibody (mAb) that is designed to target galectin-9, a protein that regulates immunosuppression and is prominently expressed in hard-to-treat cancers, such as colorectal cancer, or CRC, cholangiocarcinoma, pancreatic cancer and others.

LYT-210
Anti-Delta-1 MAb
Solid tumors

Preclinical

Solid tumors

>50K/year U.S. (Metastatic CRC)
>28K/year U.S. (Metastatic pancreatic cancer)
>4K/year U.S. (Metastatic cholangiocarcinoma)


LYT-210 is an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).

LYT-300
Oral Allopregnanolone
Neurological indications

Preclinical

Neurological indications

LYT-300 is an oral form of FDA-approved allopregnanolone, which is currently marketed in the U.S. as ZulressoTM and administrated as a 60-hour intravenous infusion. Despite FDA approval, the 60-hr IV infusion has greatly limited the usage of Zulresso. Achieving oral bioavailability for allopregnanolone, a natural neurosteroid, may enable its usage across a range of neurological conditions.
Phase completedPhase in progress

The BIG Idea - Moving medicine forward at PureTech

Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out
Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out

Relationships with multiple major pharma companies or their investment arms